Follow
Thomas John
Thomas John
Medical Oncologist, Peter MacCallum Cancer Centre
Verified email at petermac.org
Title
Cited by
Cited by
Year
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
SS Ramalingam, J Vansteenkiste, D Planchard, BC Cho, JE Gray, Y Ohe, ...
New England Journal of Medicine 382 (1), 41-50, 2020
25062020
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
YL Wu, M Tsuboi, J He, T John, C Grohe, M Majem, JW Goldman, ...
New England Journal of Medicine 383 (18), 1711-1723, 2020
16212020
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ...
The Lancet Oncology 21 (2), 271-282, 2020
16102020
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open …
L Paz-Ares, TE Ciuleanu, M Cobo, M Schenker, B Zurawski, J Menezes, ...
The Lancet Oncology 22 (2), 198-211, 2021
11942021
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology …
S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ...
Advances in anatomic pathology 24 (6), 311-335, 2017
7952017
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology …
S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ...
Advances in anatomic pathology 24 (5), 235-251, 2017
6952017
Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
SS Ramalingam, JCH Yang, CK Lee, T Kurata, DW Kim, T John, ...
Journal of Clinical Oncology 36 (9), 841-849, 2018
5722018
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
A Drilon, S Siena, R Dziadziuszko, F Barlesi, MG Krebs, AT Shaw, ...
The Lancet Oncology 21 (2), 261-270, 2020
4712020
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
M Tsuboi, RS Herbst, T John, T Kato, M Majem, C Grohé, J Wang, ...
New England Journal of Medicine 389 (2), 137-147, 2023
3552023
Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
VA Papadimitrakopoulou, YL Wu, JY Han, MJ Ahn, SS Ramalingam, ...
Annals of Oncology 29, viii741, 2018
2702018
Molecular predictive and prognostic markers in non-small-cell lung cancer
LE Coate, T John, MS Tsao, FA Shepherd
The lancet oncology 10 (10), 1001-1010, 2009
2622009
Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non–small-cell lung cancer: updated results from the phase III randomized ADAURA trial
RS Herbst, YL Wu, T John, C Grohe, M Majem, J Wang, T Kato, ...
Journal of Clinical Oncology 41 (10), 1830-1840, 2023
2542023
Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of …
T John, G Liu, MS Tsao
Oncogene 28 (1), S14-S23, 2009
2492009
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
VA Papadimitrakopoulou, TS Mok, JY Han, MJ Ahn, A Delmonte, ...
Annals of Oncology 31 (11), 1536-1544, 2020
2402020
Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors
PL Chia, P Mitchell, A Dobrovic, T John
Clinical epidemiology, 423-432, 2014
2222014
Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP
M Lu, H Breyssens, V Salter, S Zhong, Y Hu, C Baer, I Ratnayaka, ...
Cancer cell 23 (5), 618-633, 2013
2032013
The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non–small cell lung cancer
T John, D Kohler, M Pintilie, N Yanagawa, NA Pham, M Li, D Panchal, ...
Clinical cancer research 17 (1), 134-141, 2011
1962011
Nivolumab (NIVO)+ ipilimumab (IPI)+ 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell …
M Reck, TE Ciuleanu, MC Dols, M Schenker, B Zurawski, J Menezes, ...
Journal of Clinical Oncology 38 (15_suppl), 9501-9501, 2020
1912020
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
M Reck, TE Ciuleanu, M Cobo, M Schenker, B Zurawski, J Menezes, ...
ESMO open 6 (5), 100273, 2021
1882021
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
EF Lee, TJ Harris, S Tran, M Evangelista, S Arulananda, T John, ...
Cell death & disease 10 (5), 342, 2019
1802019
The system can't perform the operation now. Try again later.
Articles 1–20